Targeting gene modifications to improve treatments for prostate cancer
Official title: Combinational targeting histone and RNA modifications in prostate cancer
Funded at Northwestern University at Chicago · NIH-11107533 · Data updated 2026-11-12
This study is exploring new ways to treat advanced prostate cancer by looking at a protein called EZH2 that can affect how cancer cells behave, with the hope of finding better treatment options that work well with what patients are already receiving.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | April 9, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $570,096 |
| NIH project number | 1R01CA300246-01 |
| Project ID | NIH-11107533 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those who have shown resistance to current therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have advanced disease may not benefit from this research.
What this research studies
This research investigates new therapeutic strategies for advanced prostate cancer by targeting both genetic and epigenetic modifications. It focuses on the role of the EZH2 protein, which is linked to poor patient outcomes, and how it affects RNA stability and splicing. By understanding these mechanisms, the research aims to develop more effective treatment options that could work alongside existing therapies. Patients may benefit from innovative approaches that could enhance their treatment response and survival rates.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with advanced prostate cancer, potentially increasing survival rates.
How similar studies have gone: Previous research has shown promising results in targeting epigenetic modifications in cancer treatment, indicating potential for success in this novel approach.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Cao, Qi — Northwestern University at Chicago
- Study coordinator: Cao, Qi
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.